Experience With Etanercept, Tocilizumab and Interleukin-1 Inhibitors in Systemic Onset Juvenile Idiopathic Arthritis Patients From the BIKER Registry

Gerd Horneff; Anna Carina Schulz; Jens Klotsche; Anton Hospach; Kirsten Minden; Ivan Foeldvari; Ralf Trauzeddel; Gerd Ganser; Frank Weller-Heinemann; Johannes Perter Haas


Arthritis Res Ther. 2017;19(256) 

In This Article


The results revealed that a large proportion of patients with sJIA had a significant response to treatment, especially with TOC or with IL-1i. After 6 months on treatment, JADAS remission criteria were reached by up to 52% of patients while 61–68% reached JADAS minimal disease activity criteria. ETA has been used in the past. The rate of patients reaching remission is markedly lower than upon treatment with IL-1i or TOC. Its use in systemic JIA has markedly decreased in Germany. Moreover, it was used in patients presenting with arthritis with fewer systemic features[1] as suggested in the recommendation from the USA.